26-Dec-2025
Genmab–BioNTech Cancer Antibody Trial Ends Early: What Investors Need to Know
TipRanks (Fri, 26-Dec 11:30 AM ET)
Globe Newswire (Thu, 18-Dec 4:45 AM ET)
Globe Newswire (Tue, 9-Dec 7:00 AM ET)
Market Chameleon (Mon, 8-Dec 2:09 AM ET)
Globe Newswire (Sat, 6-Dec 3:30 PM ET)
BioNTech Achieves Minimum Condition in CureVac Exchange Offer
Globe Newswire (Wed, 3-Dec 9:01 AM ET)
Market Chameleon (Wed, 26-Nov 2:49 AM ET)
Globe Newswire (Wed, 26-Nov 7:30 AM ET)
BioNTech Lifts Revenue Guidance and Highlights Oncology Advances Despite Reporting Q3 Net Loss
Market Chameleon (Mon, 3-Nov 2:12 AM ET)
BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update
Globe Newswire (Mon, 3-Nov 6:45 AM ET)
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
Biontech Se - American Depositary Shares trades on the NASDAQ stock market under the symbol BNTX.
As of December 26, 2025, BNTX stock price declined to $94.52 with 469,055 million shares trading.
BNTX has a beta of 0.84, meaning it tends to be less sensitive to market movements. BNTX has a correlation of 0.12 to the broad based SPY ETF.
BNTX has a market cap of $22.72 billion. This is considered a Large Cap stock.
Last quarter Biontech Se - American Depositary Shares reported $2 billion in Revenue and -$.14 earnings per share. This beat revenue expectation by $586 million and missed earnings estimates by -$.89.
In the last 3 years, BNTX traded as high as $176.67 and as low as $76.53.
The top ETF exchange traded funds that BNTX belongs to (by Net Assets): IBB, FBT, FNDF, TCAF, SPDW.
BNTX has underperformed the market in the last year with a price return of -16.9% while the SPY ETF gained +16.0%. BNTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -3.6% and -0.3%, respectively, while the SPY returned +4.6% and +1.5%, respectively.
BNTX support price is $93.33 and resistance is $96.73 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BNTX shares will trade within this expected range on the day.